@article{b1912fe1dd794c5b929755768748a5f7,
title = "Purification of cardiomyocytes and neurons derived from human pluripotent stem cells by inhibition of de novo fatty acid synthesis",
abstract = "Here we describe a protocol to obtain highly pure cardiomyocytes and neurons from human induced pluripotent stem cells (hiPSCs) via metabolic selection processes. Compared to conventional purification protocols, this approach is easier to perform and scale up and more cost-efficient. The protocol can be applied to hiPSCs and human embryonic stem cells. For complete details on the use and execution of this protocol, please refer to Tohyama et al. (2016) and Tanosaki et al. (2020).",
keywords = "Cell Differentiation, Cell culture, Cell isolation, Stem Cells",
author = "Sho Tanosaki and Tomohiko Akiyama and Sayaka Kanaami and Jun Fujita and Ko, {Minoru S.H.} and Keiichi Fukuda and Shugo Tohyama",
note = "Funding Information: The authors thank the Center for iPSC Research and Application and Kyoto University for providing the hiPSC lines (253G4 and 201B7). This work was mainly supported by Projects for Technological Development, Research Center Network for Realization of Regenerative Medicine by Japan Agency for Medical Research and Development (grant 20bm0404023h0003 to S. Tohyama), and was partly supported by JSPS KAKENHI (grant 20H03768 to S. Tohyama) and a research grant from Heartseed Inc. Funding Information: The authors thank the Center for iPSC Research and Application and Kyoto University for providing the hiPSC lines (253G4 and 201B7). This work was mainly supported by Projects for Technological Development, Research Center Network for Realization of Regenerative Medicine by Japan Agency for Medical Research and Development (grant 20bm0404023h0003 to S. Tohyama), and was partly supported by JSPS KAKENHI (grant 20H03768 to S. Tohyama) and a research grant from Heartseed Inc. S.K. and T.A. performed the experiments. S. Tanosaki, T.A. and S. Tohyama wrote the original draft. S. Tohyama, M.S.H.K. and K.F. reviewed and edited the manuscript. S. Tohyama, J.F. M.S.H.K. and K.F. supervised the study. S. Tohyama and K.F. acquired funding. S. Tanosaki, J.F. K.F. and S. Tohyama have a patent pending related to this work. K.F. is a co-founder and CEO of Heartseed, Inc. S. Tohyama is an advisor of Heartseed, Inc. J.F. K.F. and S. Tohyama own equity in Heartseed Inc. M.S.H.K. is a founder, CSO, and interim CEO of Elixirgen Scientific, Inc. The remaining authors declare no competing interests. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = jun,
day = "17",
doi = "10.1016/j.xpro.2022.101360",
language = "English",
volume = "3",
journal = "STAR Protocols",
issn = "2666-1667",
publisher = "Cell Press",
number = "2",
}